Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings

– Data from Lymphoseek studies to be presented at the International Conference on Innovative Approaches in Head and Neck Oncology, AACR-SNMMI and SSO –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek® (technetium Tc 99m tilmanocept) Injection studies in breast cancer and melanoma or head and neck cancer are being presented at the following conferences: The 4th International Conference on Innovative Approaches In Head And Neck Oncology in Barcelona, Spain, the joint meeting of AACR and the Society of Nuclear Medicine and Molecular Imaging in San Diego, CA and the 66th Society of Surgical Oncology Cancer Symposium in Washington, DC. Details of the poster presentations are listed below.

Conference: 4th International Conference on Innovative Approaches in Head And Neck Oncology (ICHNO)
Date: February 7-9, 2013
Location: Barcelona, Spain

Poster Title: Utilization of Tc99m-tilmanocept to assess sentinel lymph node status in HNSCC patients

Author: Stephen Y. Lai, MD, PhD, FACS, The University of Texas MD Anderson Cancer Center, Houston, TX

Conference: American Association for Cancer Research (AACR) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Date: February 27 – March 2, 2013
Location: San Diego, CA

Poster Title: Evaluation of human mannose receptor (CD206) binding of Tc 99m tilmanocept: A novel bio-targeted sentinel node mapping agent for solid tumors

Author: Michael Blue, MD, Senior Medical Director, Navidea Biopharmaceuticals

Conference: 66th Society of Surgical Oncology Cancer Symposium
Date: March 6-9, 2013
Location: Washington, DC
Utilization of Tc 99m tilmanocept to evaluate the pathology status of sentinel lymph nodes vs. elective neck dissection in patients with intraoral HNSCC: A preliminary evaluation against technetium Tc 99m sulfur colloid in the ACOSOG-Z0360

Author: Stephen Y. Lai, MD, PhD, FACS, The University of Texas MD Anderson Cancer Center, Houston, TX

About Lymphoseek®

Lymphoseek® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancers such as breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer, 76,000 new cases of melanoma and 67,000 new cases of head and neck cancers are expected to be diagnosed in the United States in 2012.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScan™ – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO – (614) 822-2330

Source: Navidea Biopharmaceuticals, Inc.